BackTable Tumor Board

BackTable Tumor Board is a multi-disciplinary podcast for healthcare professionals that play an active role in cancer care.

BackTable Tumor Board is a health podcast hosted by Unknown Host, with 76 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

Unknown Host hosts BackTable Tumor Board, a health show with 76 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  BackTable Tumor Board

  Ep. 77 AI's Impact on Oncology Practice with Dr. Larry Bilbrey

  Aug 18, 202652 min

  Where is AI already making oncology practice more efficient, and where does human expertise remain irreplaceable? In this episode of BackTable Tumor Board, medical oncologists Dr. Kate Baker and Dr. Larry Bilbrey discuss how AI is improving oncology workflow, such as scribing and information retrieval, but is far from replacing clinicians, especially for hands-on care. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps 00:00 - Introduction 03:17 - Evolution of Technology08:12 - The Role of AI in Healthcare Workflow18:57 - Prioritizing Provider-First Approach for Use of AI24:08 - Liability Disclosure Audits28:48 - Human Audits in Quality Assurance32:55 - Patients Using ChatGPT40:05 - The Potential of AI Care Companions42:59 - The Future of AI --- More about this episode Despite its advantages, the doctors discuss using AI in higher-stakes clinical settings with caution, as it is often limited by accuracy, liability, regulation, culture, and patient acceptance. They emphasize the importance of transparent patient disclosure and human auditing for quality assurance, as well as a focus on using AI for repetitive digital tasks rather than supporting clinical decisions. They also address patient use of ChatGPT, the potential of AI companions for helping patients navigate care, and the future of AI in the years ahead. --- BackTable Tumor Board is the go-to multidisciplinary podcast for medical oncologists, surgical oncologists, and other healthcare professionals that play an active role in cancer care. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

  ListenShow Notes
• 

  BackTable Tumor Board

  Ep. 76 GU Oncology: ASCO Highlights & Impacts on Practice with Dr. Alan Tan

  Aug 11, 202629 min

  Is GU oncology entering a new era of early intensification and precision therapy? On this episode of the BackTable Tumor Board Podcast, Dr. Katy Beckermann and Dr. Alan Tan break down the latest GU oncology highlights from ASCO, including key updates in prostate, renal cell, and urothelial carcinoma. They discuss new data supporting HRR/BRCA-focused therapy in HSPC, the importance of early biomarker testing, and ongoing debates about overtreatment and real-world practice impact. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps 00:00 - Introduction01:56 - Frontline Prostate Cancer & TALAPRO-3 Highlights07:11 - PROTEUS Plenary Breakdown & Controversies13:47 - RCC Rampart and ctDNA19:47 - Bladder EV Pembro Updates23:34 - Next-Gen Nectin-4 ADC26:51 - Wrap-Up --- More about this episode The conversation covers the PROTEUS trial and perioperative intensification, RAMPART and Keynote-564 ctDNA findings in RCC, and new standards in perioperative bladder cancer treatment with EV plus pembrolizumab. Drs. Tan and Beckermann also discuss next-generation ADCs, pharmacogenomic toxicity considerations, and the promise of AI and ctDNA for patient selection and de-escalation strategies in advanced GU cancers. --- Resources TALAPRO-3 Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa2604126 PROTEUS Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa2603878 RAMPART Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa1107494 KEYNOTE-564 ctDNA Biomarker Sub-Studyhttps://www.urotoday.com/conference-highlights/asco-2026/asco-2026-kidney-cancer/169387-asco-2026-ctdna-analysis-in-participants-with-rcc-treated-with-adjuvant-pembrolizumab-in-the-keynote-564-trial.html --- BackTable Tumor Board is the go-to multidisciplinary podcast for medical oncologists, surgical oncologists, and other healthcare professionals that play an active role in cancer care. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

  ListenShow Notes
• 

  BackTable Tumor Board

  Ep. 75 Applying CheckMate 8HW: Practical Updates for MSI-High CRC with Dr. Cathy Eng

  Aug 4, 202627 min

  Is it time to rethink the definition of “cure” for stage IV colorectal cancer? In this episode of BackTable Tumor Board, medical oncologist Jun Gong interviews Dr. Cathy Eng about updates from the phase III CheckMate-8HW trial in centrally confirmed MSI-high/dMMR metastatic colorectal cancer, comparing nivolumab/ipilimumab, nivolumab, and chemotherapy. They discuss initial findings demonstrating improved progression-free survival and response rates with combination immunotherapy, as well as safety considerations and how comorbidities and frailty guide the choice between single-agent and combination regimens. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by Bristol Myers Squibb https://www.bms.com/ --- Timestamps00:00 - Introduction01:40 - Trial Design Breakdown03:37 - Initial Efficacy Results09:47 - ASCO Update Highlights13:18 - Induction Tolerability15:12 - Rechallenge After Relapse17:26 - COMMIT Trial Breakdown22:55 - BRAF Mutant MSI High Strategy24:54 - Closing Remarks --- More about this episodeThe conversation reviews the ASCO post-hoc update with 55.1 months follow-up, highlighting higher 4-year survivor rates and longer treatment-free intervals for patients on combination therapy. Drs. Gong and Eng also discuss the implications of the underpowered COMMIT trial, the unexpectedly poor performance of atezolizumab monotherapy, and why chemo-immunotherapy is not currently recommended. The episode concludes with impressions from ESMO GI, including a negative second-line KRAS G12C adagrasib plus EGFR study, and broader reflections on the evolving definition of cure in advanced colorectal cancer. --- Resources Checkmate-8HW Phase III Trialhttps://www.nejm.org/doi/full/10.1056/NEJMoa2402141 Keynote 177https://www.nejm.org/doi/full/10.1056/NEJMoa2017699 COMMIT Phase III Trialhttps://ascopubs.org/doi/10.1200/JCO.2026.44.2_suppl.14 --- BackTable Tumor Board is the go-to multidisciplinary podcast for medical oncologists, surgical oncologists, and other healthcare professionals that play an active role in cancer care. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty.► https://www.backtable.com/app

  ListenShow Notes
• 

  BackTable Tumor Board

  Ep. 74 Systemic Therapy Strategies for Treating Neuroendocrine Tumors with Dr. Chih-Yi "Andy" Liao and Dr. Robert Ramirez

  Jul 28, 202647 min

  What first-line therapies should be considered for patients with higher-grade, metastatic neuroendocrine tumors (NETs)? In this new episode of BackTable Tumor Board, Drs. Lingling Du, Chih-Yi Liao, and Robert Ramirez discuss the use of systemic or radioligand therapies for metastatic well-differentiated NETs. --- Get the BackTable apphttps://www.backtable.com/app --- This podcast is supported by Novartishttps://www.novartis.com/ --- Timestamps 00:00 - Introduction 02:31 - NGS Testing in NETs05:45 - Starting with Somatostatin Analog (SSA)08:01 - NETTER-2 Trial and Front-Line PRRT11:58 - High Dose SSA After Progression14:59 - Sequencing Systemic Therapy Options18:56 - Picking the Right PRRT Candidate21:28 - PRRT: Responses, Toxicities & Risks31:58 - Lung NET Treatment Strategy34:16 - Using Immunotherapy for Low-Grade NET36:05 - First-Line Treatment for Poorly Differentiated Extrapulmonary Neuroendocrine Carcinoma41:40 - What’s Next: Ongoing Clinical Trials --- More about this episode The doctors cover the use of next generation sequencing for newly diagnosed patients, highlighting that although results rarely changes upfront management, it can occasionally reveal actionable findings such as high tumor mutation burden and mismatch repair deficiency. In addition to NGS, care should prioritize imaging, pathology review, and multidisciplinary collaboration and planning. They then review several clinical trials, including the NETTER-2 and CLARNET FORTE trials to evaluate the role of peptide receptor radionuclide therapy (PRRT) and somatostatin analog (SSA) therapy while considering sequencing of multimodal treatments. The episode wraps up with ongoing and future clinical trials investigating other potential therapies for NETs. --- Resources Phase 3 NETTER-2 Trialhttps://pubmed.ncbi.nlm.nih.gov/38851203/ Phase 2 CLARINET FORTE Trialhttps://pubmed.ncbi.nlm.nih.gov/34597974/ Corticosteroid Prophylaxis for for Patient with Neuroendocrine Tumorshttps://pmc.ncbi.nlm.nih.gov/articles/PMC12609636/ Phase 3 CABINET Trial (Alliance A021602)https://pubmed.ncbi.nlm.nih.gov/41524552/ SWOG S2012 Trialhttps://www.asco.org/abstracts-presentations/213198 DAREON-Lung-1 Trialhttps://clinicaltrials.gov/study/NCT07472517 212-lead VMT-ɑ-NET Safety Studyhttps://clinicaltrials.gov/study/NCT06148636 RayzeBio Phase 3 ACTION-1 Studyhttps://www.ncf.net/clinical-trials-1/action-1%3A-alpha-prrt-with-ac-225-in-gep-nets RayzeBio Phase I RYZ401 Trialhttps://clinicaltrials.gov/study/NCT07165132 Phase I & II CHM-2101 Trialhttps://ascopubs.org/doi/10.1200/JCO.2026.44.16_suppl.2536 --- BackTable Tumor Board is the go-to multidisciplinary podcast for medical oncologists, surgical oncologists, and other healthcare professionals that play an active role in cancer care. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

  ListenShow Notes
• 

  BackTable Tumor Board

  Ep. 73 Comprehensive Care in Breast Cancer Survivorship with Dr. Lindsay Peterson

  Jul 21, 202643 min

  When breast cancer treatment ends, recurrence surveillance can easily overshadow the symptoms and concerns that continue to affect daily life. In this episode of the BackTable Tumor Board Podcast, Dr. Kate Baker and Dr. Lindsay Peterson discuss how effective survivorship care can address recurrence anxiety, endocrine therapy toxicities, bone health, sexual health, and the broader emotional and practical needs of patients after treatment. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps00:00 - Introduction03:29 - First Survivorship Visit & Clinic Workflow13:40 - Addressing Recurrence Anxiety in Breast Cancer Survivors18:41 - Endocrine Therapy Side Effects20:01 - Managing Aromatase Inhibitor-Induced Arthralgias & Joint Pain23:56 - Hot Flash Treatment Options26:20 - Addressing Sexual Side Effects30:14 - Bone Health, Bisphosphonates & Dental Clearance35:20 - Calcium and Vitamin D Dosing in Diet vs Supplement36:54 - Survivorship Care Takeaways --- More about this episode The conversation begins with different models for survivorship clinics and the priorities of an initial survivorship visit. Drs. Baker and Peterson explore how clinicians can address recurrence anxiety while also evaluating patients’ emotional, social, and financial needs. They then review common endocrine therapy toxicities, including arthralgias, hot flashes, fatigue, reduced bone density, and sexual side effects. The discussion includes practical strategies for managing aromatase inhibitor–associated joint pain, available treatments for hot flashes, and approaches to sexual health concerns. Drs. Baker and Peterson also examine bone-health management, including bisphosphonate therapy, dental clearance, and appropriate calcium and vitamin D intake. The episode concludes with guidance for building a more comprehensive and patient-centered approach to breast cancer survivorship. --- BackTable Tumor Board is the go-to multidisciplinary podcast for medical oncologists, surgical oncologists, and other healthcare professionals that play an active role in cancer care. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

  ListenShow Notes

Recent guests on BackTable Tumor Board. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.